[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ADVANCED MARKER DISCOVERY S.L.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":118},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,62,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100584480","development-and-validation-of-a-blood-test-for-early-diagnosis-of-colorectal-cancer-100584480",false,"NCT06889883","Development and Validation of a Blood Test for Early Diagnosis of Colorectal Cancer","Development and Validation of a Blood Test for Early Diagnosis of Colorectal Cancer Based on Molecular Markers and Risk Factors Identified With Artificial Intelligence Tools","ColoDix","Inclusion Criteria:\n\n* Patients over the age of 18 who are able to understand the participant information and sign the informed consent.\n* Patients who are going to undergo colonoscopy or surgical resection for tumor (CRC).\n\nExclusion Criteria:\n\n* Patients who had developed any type of cancer in the 5 years prior to their participation in this study.\n* Patients who have received previous chemotherapy or radiotherapy.\n* Patients diagnosed with non-advanced adenomas, serrated polyps, Familial Adenomatous Polyposis or Lynch Syndrome.\n* Patients with inadequate bowel preparation for colonoscopy.\n* Patients who have undergone colonoscopy\u002Fpolipectomy in the previous 5 years.\n* Patients with hemolyzed plasma.",true,"ALL","18 Years",{"count":21,"type":22},510,"ESTIMATED","30 Days","OBSERVATIONAL","This is a prospective, multicenter, case-control study. The aim is to develop an optimized algorithm by combining the levels of molecular markers in plasma together with risk factors for developing colorectal cancer and clinical data of patients diagnosed with CRC or AA and healthy individuals.",[27,28],"Colorectal Carcinoma","Advanced Adenomas (AA)","RECRUITING","2025-09-29",{"date":32,"type":33},"2025-10-01","ACTUAL",{"date":35,"type":33},"2023-06-06",{"date":37,"type":22},"2025-12-31",{"name":39,"class":40},"ADVANCED MARKER DISCOVERY S.L.","INDUSTRY",9,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":24,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":55,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100584477","observational-cross-reactivity-study-for-colorectal-cancer-diagnosis-100584477","NCT06889844","Observational Cross-reactivity Study for Colorectal Cancer Diagnosis","Observational Cross-reactivity Study to Evaluate the Specificity of a Blood Test for Colorectal Cancer Diagnosis Based on Molecular Markers and Risk Factors Identified With Artificial Intelligence Tools","Inclusion Criteria:\n\n* Patients older than 18 years of age at the time of blood sample collection.\n* Subjects must be able to understand the information provided on the participant information sheet, must consent to participate in the study, and must sign the informed consent form.\n* Patients diagnosed with only one type of cancer (no colorectal cacner) or gastrointestinal disease.\n\nExclusion Criteria:\n\n* Patients who have received previous chemotherapy or radiotherapy.\n* In case of diagnosis of a tumor: patients who have undergone total or partial surgical resection of the tumor.\n* Patients with a personal history of advanced or non-advanced colorectal adenoma, serrated lesions, colorectal cancer, familial adenomatous polyposis or Lynch syndrome.\n* Patients without appropriate staging or diagnosis.\n* Patients with hemolyzed plasma.",{"count":50,"type":22},250,"1 Day","The objective of this observational study is to evaluate the false positive rate of the blood test based on molecular biomarkers and risk factors. A total of 250 patients diagnosed with various cancers and gastrointestinal diseases will be enrolled. The main question to be answered is\n\nDoes the blood test have a low false positive rate in the main study population?\n\nParticipants will donate a blood sample as part of their regular medical care for cancer diagnosis and give the consent to know their clinical risk factors.",[54],"Colorectal Cancer",{"date":32,"type":33},{"date":57,"type":33},"2023-04-17",{"date":59,"type":22},"2025-12",{"name":39,"class":40},5,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":17,"sex":18,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":91,"locationsCount":92},"100569614","exploring-participant-preference-for-screening-methods-and-experience-into-colorectal-cancer-screening-programme-100569614","NCT06696534","Exploring Participant Preference for Screening Methods and Experience Into Colorectal Cancer Screening Programme","MS-Care","Inclusion Criteria:\n\n* Participants ages from 50 to 69 years (both included) at the time of informed consent signed.\n* Participants invited to participate in population-based screening programme who are eligible to undertake FOBT at the Primary Health Care Center.\n* Participants should sign an informed consent. They must understand the nature, significance, implications, and risks of the clinical study before signing the informed consent form.\n\nExclusion Criteria:\n\n* Participants who have not delivery a stool sample in the Primary Health Care Center before signing the informed consent form.\n* Participants with a previous colonoscopy in consequence of a FOBT positive result.\n* Participants who are in a dependent personal or non-medical relationship with the Sponsor or the Investigators.","50 Years","69 Years",{"count":72,"type":22},1000,"INTERVENTIONAL",[75],"NA","The goal of this low-risk interventional study is to analyze participants' assessment of colorectal cancer screening program through screening method preference and experience after FOBT analysis in screaned participant population for colorectal cancer; could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. The main aims to answer are:\n\n* Values of experience of participants into screening programme.\n* Values of preferences of participants for screening methods.\n\nParticipants will answer two questionnaires and they'll be given their information and clinical data to investigator or health personnel.",[78,79],"Screening for Colon Cancer","Survey and Questionnaire",[81,82,83,84,85],"colorectal cancer","screening programme","experience","preference","questionnaire",{"date":87,"type":33},"2025-10-02",{"date":89,"type":33},"2025-05-19",{"date":59,"type":22},{"name":39,"class":40},2,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":17,"sex":18,"minAge":69,"maxAge":70,"enrollmentInfo":100,"targetDuration":4,"studyType":73,"phases":102,"briefSummary":103,"conditions":104,"keywords":108,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":117,"locationsCount":92},"100570160","evaluation-of-prevecols-efficiency-as-a-second-line-method-for-the-early-colorectal-cancer-detection-100570160","NCT06703632","Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection","MS-Prevecol","Inclusion Criteria:\n\n* Participants ages from 50 to 69 years (both included) at the time of informed consent signed.\n* Participants should sign an informed consent. They must understand the nature, significance, implications, and risks of the clinical study before signing the informed consent form.\n* Participants with a positive result of FIT\u002FFOBT analysis referred to the gastroenterology department who are eligible to undertake colonoscopy as a regular procedure of the colorectal cancer screening programme.\n* Participants asymptomatic, average risk for CRC. Average risk is defined as those individuals who are age 50 or over with no history of adenoma, colorectal cancer, or inflammatory bowel disease, and with no family history of CRC (first degree relatives).\n\nExclusion Criteria:\n\n* Participants who have developed any another type of cancer in the 5 years prior to their participation in the study.\n* Participants who have previously received chemotherapy or radiotherapy (5 years).\n* Participants previously or currently diagnosed with Familiar Adenomatous Polyposis or Lynch Syndrome or Inflammatory Bowel Disease.\n* Inadequate intestinal preparation for colonoscopy with BBPS score ≤1 in any colon section, excluding diagnostic of CRC.\n* Participants who have undergone polypectomy in the previous 5 years.\n* Hemolysis of blood sample or absence of blood sample.\n* Participants who are arrested at judicial or official request\n* Participants who are in a dependent personal or non-medical relationship with the Sponsor or the investigator.",{"count":101,"type":22},4538,[75],"The objective of this low-risk interventional study is to evaluate whether the PreveCol® test has sufficient efficiency to be considered as a second-line method for the detection of both colorectal cancer and advanced adenomas when used prospectively in the screening population with a previous positive FOBT result, which could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. The main aims to be answered are:\n\n* Values of efficacy, efficiency, impact and safety of PreveCol.\n* Values of preferences of participants for screening methods.\n* Values of PREMs into screening programme.\n\nParticipants will provide a blood sample prior to a screening colonoscopy, and complete two questionnaires. They will give their sample, information and clinical data to the investigator or health care personnel.",[78,105,79,27,106,107],"Blood Samples","Colon Adenocarcinoma","Precancerous Lesion of Colon",[81,82,109,110,85],"liquid biopsy","second line","2025-02-25",{"date":113,"type":33},"2025-02-27",{"date":115,"type":33},"2025-01-14",{"date":59,"type":22},{"name":39,"class":40},""]